Journal ArticleOPEN ACCESS

Liraglutide (Saxenda®) for the treatment of obesity: a commentary on NICE Technology Appraisal 664

  • Kahal H
  • Mohammed K
  • Lonnen K
  • et al.
British Journal of Diabetes (2021) 21(1) 120-122
DOI: 10.15277/bjd.2021.298
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Saxenda, Liraglutide 3.0 mg, is a glucagon-like peptide-1 (GLP-1) analogue that is licensed for the treatment of adults with overweight and obesity. In this commentary we review the NICE technology appraisal (TA664) on the use of Saxenda in the National Health Service (NHS) and its implication in clinical practice.

Cite

CITATION STYLE

APA

Kahal, H., Mohammed, K., Lonnen, K., Sathyapalan, T., & Walton, C. (2021). Liraglutide (Saxenda®) for the treatment of obesity: a commentary on NICE Technology Appraisal 664. British Journal of Diabetes, 21(1), 120–122. https://doi.org/10.15277/bjd.2021.298

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free